The biggest names behind biotech stocks are investing richly in artificial intelligence with the goal of speeding up drug development.

The hedge fund legend has bet much of the family office on this one diagnostics company.

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how biotechnology stocks fared in Q2, starting with Natera (NASDAQ:NTRA).

NVIDIA and top institutional investors are piling into AI infrastructure, with 13F filings revealing bets on Intel, CoreWeave, Nebius and more.

NTRA is using its Latitude MRD test in Kupando's Phase 1 skin cancer trial to track ctDNA and characterize response to KUP-101.

Natera stock has delivered a very large 3 year gain, yet its valuation checks send mixed signals, with a Discounted Cash Flow (DCF) estimate suggesting the share price sits well below intrinsic value while market multiples point to an expensive stock. The share price has risen by roughly 4.9x over 3 years, which puts a lot of past optimism into the current valuation. Recent progress in expanding the use of its tests in oncology and related clinical settings can support long term growth...

Natera (NTRA) has drawn fresh attention after announcing a new collaboration that puts its Latitude molecular residual disease test into a Phase 1 clinical trial for Kupando Therapeutics’ lead immunotherapy candidate, KUP-101. See our latest analysis for Natera. The latest collaboration news comes after an active stretch for Natera, with recent earnings, raised 2026 revenue guidance and regulatory milestones in Japan helping underpin strong momentum. The stock’s share price return of 60.97%...

Natera (NASDAQ:NTRA) Chief Financial Officer Mike Brophy said the company delivered strong second-quarter momentum across its women’s health, oncology and organ health businesses, citing record Signatera volumes, continued revenue and average selling price strength, improved gross margins and narrow

Natera’s second quarter results were positively received by the market, driven by robust sales volume growth and ongoing momentum in both established and emerging product lines. Management attributed the quarter’s strength to record-breaking test volumes—particularly for Signatera in oncology—and the successful launch of an enhanced Panorama prenatal test. CEO Steven Chapman highlighted increased adoption across tumor types and cited critical milestones, including FDA and Japanese regulatory app

Oncology volumes jumped 57.2% on MRD adoption gains.

TEM's FDA approval for xT could unlock $85 million in annual revenue from higher pricing, with bigger gains tied to xF.

TEM's faster growth, rising data demand and reimbursement potential strengthen the bull case, but high valuation and cash burn keep risks in focus.

Genetic testing company Natera (NASDAQ:NTRA) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 37.7% year on year to $752.8 million. The company’s full-year revenue guidance of $2.88 billion at the midpoint came in 3% above analysts’ estimates. Its non-GAAP loss of $0.47 per share was 12% above analysts’ consensus estimates.

Moshkevich's non-discretionary sale was executed to cover tax withholding on vesting RSUs under a Rule 10b5-1 plan.

This sale was executed under a pre-arranged Rule 10b5-1 trading plan.

This sale was non-discretionary and executed under a Rule 10b5-1 plan to cover tax withholding from RSU vesting.

This was a non-discretionary sale to cover tax withholding on vesting equity awards under a Rule 10b5-1 plan.

Sheena executed 9,150 shares under a pre-established trading plan adopted in December 2025.

Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who lost money in tech stocks during 2022.

In early August 2026, Natera filed an US$849.22 million shelf registration for 3,200,000 common shares tied to its employee stock plans, shortly after reporting record quarterly test volumes and raising full-year 2026 revenue guidance to US$2.85 billion–US$2.91 billion. The company’s push to expand regulatory approvals for its Signatera molecular residual disease test, including a new companion diagnostic application in Japan for muscle-invasive bladder cancer, underpins its efforts to...

Natera and Halozyme Therapeutics saw gains above 15%, led by bullish Wall Street commentary after better-than-expected second-quarter results.

SpaceX's gravitational pull is undeniable. That's why it's unsurprising that a few offhand remarks in SpaceX's earnings call on Tuesday still managed to jolt stocks in the further reaches of the company's orbit.

Natera stock surged Friday after reporting blowout volume for its cancer-detecting blood test, Signatera, in the second quarter.

Moby summary of Natera, Inc.'s Q2 2026 earnings call

Natera (NASDAQ:NTRA) reported second-quarter 2026 revenue of approximately $753 million, up about 38% from a year earlier, as record testing volumes and higher average selling prices supported growth across its oncology, women’s health and organ health businesses. The company processed approximatel

Natera Inc (NTRA) delivered a record-breaking quarter with 38% revenue growth, driven by surging Signatera volumes and key regulatory wins.

Natera (NTRA) delivered earnings and revenue surprises of 0.00% and +14.23%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Genetic testing company Natera (NASDAQ:NTRA) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 37.7% year on year to $752.8 million. The company’s full-year revenue guidance of $2.88 billion at the midpoint came in 3% above analysts’ estimates. Its GAAP loss of $0.47 per share was 8.1% above analysts’ consensus estimates.

Cancer test provider Natera is in a buy zone above a cup base ahead of second-quarter results due Thursday.

The company has made massive strides in medical diagnostics and is growing at a rapid clip.

The VistaShares Target 15 Berkshire Select Income ETF has topped Berkshire stock’s return of 3% since March 2025.

Upcoming earnings release puts Natera stock in focus Natera (NTRA) is drawing fresh attention after announcing plans to report second quarter 2026 results on August 6, 2026, after the market close, followed by a conference call and webcast. See our latest analysis for Natera. At a latest share price of US$267.76, Natera has seen short term share price momentum cool slightly over the past month, while its 90 day share price return of 29.18% and one year total shareholder return of 98.96% point...

Natera stock has delivered a very strong multi year return and now trades on valuation multiples that screen as expensive, so the question for investors is whether the recent enthusiasm already prices in much of the good news. Over the past three years, Natera has returned very roughly 5x, which sets a high bar for any further gains to be justified by fundamentals. Positive attention on the Signatera minimal residual disease test, including recent study results in Merkel cell carcinoma, can...

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.

Natera has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 9.1% to $263.44 per share while the index has gained 7.9%.

Stocks that outperform the market usually share key traits such as rising sales, expanding margins, and increasing returns on capital. The select few that can do all three for many years are often the ones that make you life-changing money.

Cathie Wood Trims AMD to Fund Bigger SpaceX Bet

Stanley Druckenmiller is skipping the mega-cap tech herd and loading up on a Mexican discount grocer, an Argentine shale producer, and a biotech that Wall Street just handed a 38% discount despite accelerating fundamentals. Here is what his latest 13F reveals about where serious money is actually moving.

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Natera (NASDAQ:NTRA) and its peers.

It may not be a familiar name, but Natera has provided better returns than Nvidia over the past 12 months.